

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Dong et al.)
Serial No. : 09/740,191) Group Art Unit: 1615
Filed : 12/19/2000) Examiner:
For : DOSAGE FORM COMPRISING LIQUID)
FORMULATION)
APR 20 2001
PATENT & TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an Information Disclosure Statement is required.
- ☐ The fee of \$ 240.00 as set forth in 37 C.F.R. § 1.17(p), as per 37 § 1.97(c), is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), a petition requesting consideration of the Information Disclosure Statement, and the petition fee of \$ 130.00 as set forth in 37 C.F.R. § 1.17(i) are also enclosed.
- ☐ Charge \$ to Deposit Account No. 01-1173 for the fee due.
- ☐ A check in the amount of \$ is enclosed for the fee due.
- ☒ The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 01-1173.

This paper is submitted in triplicate

Respectfully submitted,

Date: April 13, 2001

Robert R. Neller
Robert R. Neller, Registration No. 46,950

ALZA Corporation
1900 Charleston Road, P. O. Box 7219
Mountain View, CA 94039-7210
659.564.5171

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on: April 13, 2001(date).

ALZA CORPORATION

By:

Kathleen Sobolesko

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

ARC 2536N1

RECEIVED
APR 24 2001
TECH CENTER 1600/2800

Re Application Of: Dong et al

Serial No.

09/740,191

Filing Date

12/19/2000

Examiner

Group Art Unit

Title: **DOSAGE FORM COMPRISING LIQUID FORMULATION**

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
ARC 2556N1

In Re Application Of: **Dong et al**

Serial No.
09/740,191

Filing Date
12/19/2000

Examiner

Group Art Unit

Title: **DOSE FORM COMPRISING LIQUID FORMULATION**



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **01-1173** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on <u>April 13, 2001</u> with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
<u>Kathleen Soboleska</u> Signature of Person Mailing Correspondence
<u>Kathleen Soboleska</u> Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Robert R. Neller
Signature

Dated: April 13, 2001

Robert R. Neller
Registration No. 46,950
ALZA Corporation
950 Page Mill Road, P.O. Box 10950
Palo Alto, CA 94303-0802
650.494.5224

CC:

Applicant(s)	:	Dong et al.)	
)	Group Art Unit: 1615
Serial No.	:	09/740,191)	
)	Examiner:
Filed		12/19/2000)	
)	
For		DOSAGE FORM COMPRISING LIQUID)	
		FORMULATION)	
)	
)	
)	

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

☐ No additional fee for submission of an Information Disclosure Statement is required.

☐ The fee of \$ 240.00 as set forth in 37 C.F.R. § 1.17(p), as per 37 § 1.97(c), is also enclosed.

☒ A certification under 37 C.F.R. § 1.97(e) is also enclosed.

☐ A certification under 37 C.F.R. § 1.97(e), a petition requesting consideration of the Information Disclosure Statement, and the petition fee of \$ 130.00 as set forth in 37 C.F.R. § 1.17(i) are also enclosed.


☐ Charge \$ _____ to Deposit Account No. 01-1173 for the fee due.

☐ A check in the amount of \$ _____ is enclosed for the fee due.

☒ The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 01-1173.

This paper is submitted in triplicate

April 13, 2001


Robert R. Neller, Registration No. 46,950

By: Kathleen Salteska